Statistical Evaluation of Treatment Compliance In Children With Attention Deficit Hyperactivity Disorder

Year 2023, Volume: 18 Issue: 2, 535 - 542, 01.09.2023

Duygu Murat Uğur Tekin

https://doi.org/10.55525/tjst.1344278

Abstract

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder. Pharmacological treatment is the first option in the treatment of ADHD. Long-term treatment is required, as the course of the disease often continues throughout life. Long-term adherence to treatment in ADHD is important in terms of reducing the risk of substance use, accidents, and risk-taking behaviours. Medication adherence is very important for the successful outcome of the treatment. In this study, we aimed to evaluate the factors that may affect treatment adherence in the Turkish sample. We found that 39.6% of children with ADHD had high medication adherence accordingly Morisky Medication Adherence Scale. Medication adherence of boys and girls were similar. When the education level of mothers was compared, the education level of mothers with high medication adherence group was higher than those with poor medication adherence group, and this difference was statistically significant (p=0.013). We can say that highly educated families who learn that ADHD is a neurodevelopmental disorder and can realize the risks that may arise as a result of being untreated are more careful about drug use.

Keywords

Attention Deficit, Hyperactivity, Medication Adherence, Statistical Evaluation

Dikkat Eksikliği Hiperaktivite Bozukluğu Olan Çocuklarda Tedavi Uyumunun İstatistiksel Değerlendirilmesi

Abstract

Dikkat Eksikliği Hiperaktivite Bozukluğu (DEHB) nörogelişimsel bir bozukluktur. DEHB tedavisinde ilk seçenek tedavi farmakolojik tedavidir. Hastalığın seyri çoğu zaman yaşam boyu devam ettiği için uzun süreli tedavi gerekir. DEHB' de tedaviye uzun süreli uyumun olması, madde kullanımı, kaza ve riskli davranışlar riskini azaltabilmektedir. Tedavinin başarılı seyretmesi için ilaç uyumu çok önemlidir. Bu çalışmada tedavi uyumunu etkileyebilecek faktörleri Türkiye örnekleminde değerlendirmeyi amaçladık. Çalışmamızda Morisky İlaç Uyum Ölçeği' ne göre DEHB' li çocukların %39,6'sının ilaç uyumunun yüksek olduğunu saptadık. Kız ve erkek çocukların ilaç uyumu ise benzerdi. Annelerin eğitim durumları karşılaştırıldığında, ilaç uyumu yüksek olan grubun annelerin eğitim düzeyi, ilaç uyumu kötü olan gruba göre daha yüksekti ve bu fark istatistiksel olarak anlamlıydı (p=0,013). Sonuç olarak DEHB' nin nörogelişimsel bir bozukluk olduğunu öğrenen ve tedavi edilmediği takdirde ortaya çıkabilecek riskleri fark edebilen eğitim seviyesi yüksek ailelerin ilaç kullanımı konusunda daha dikkatli olduklarını söyleyebiliriz.

Keywords

Dikkat Eksikliği, Hiperaktivite, İlaç Uyumu, İstatistiksel Değerlendirme.

References

• Kemper A.R, Maslow G.R, Hill S, Namdari B, N.M AL, Goode AP, Sanders GD. Attention deficit hyperactivity disorder: diagnosis and treatment in children and adolescents Durham: Europe PMC, 2018.
• Ercan E.S, Unsel-Bolat G, Tufan A.E, Karakoc Demirkaya S, Bilac O, Celik G, ... & Ünal F. Effect of impairment on the prevalence and comorbidities of attention deficit hyperactivity disorder in a national survey: nation-wide prevalence and comorbidities of ADHD. Journal of Attention Disorders 2022; 26(5): 674-684.
• Klein R.G, Mannuzza S, Olazagasti M.A.R, Roizen E, Hutchison J. A, Lashua E. C, & Castellanos F. X. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch. Gen. Psychiatry 2012; 69(12): 1295-1303.
• Brown T.E. ADHD comorbidities: Handbook for ADHD complications in children and adults. Arlington: American Psychiatric Pub, 2009.
• Barnard-Brak L, Roberts B, Valenzuela E. Examining breaks and resistance in medication adherence among adolescents with ADHD as associated with school outcomes. Journal of Attention Disorders 2020; 24(8): 1148-1155.
• Kamimura-Nishimura K. I, Brinkman W. B, & Froehlich T. E. Strategies for improving ADHD medication adherence. Current psychiatry 2019; 18(8): 25.
• Charach A, Fernandez R. Enhancing ADHD medication adherence: challenges and opportunities. Current psychiatry reports 2013; 15: 1-8.
• Khan M. U, & Aslani P. Exploring factors influencing medication adherence from initiation to discontinuation in parents and adolescents with attention deficit hyperactivity disorder. Clinical pediatrics 2020; 59(3): 285-296.
• Raman S. R, Man K. K, Bahmanyar S, Berard A, Bilder S, Boukhris T, ... & Wong I. C. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. The Lancet Psychiatry 2018; 5(10): 824-835.
• Soutullo C. A, Are F, & Schield-Grant S. Factors associated with adherence to pharmacological treatment of attention deficit hyperactivity disorder (ADHD): preliminary review. Medicina 2023; 83: 27-31.
• Dopheide J. A. The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD. Am J Manag Care 2009; 15(5 Suppl): S141-50.
• Mannuzza S, Klein R. G, Bessler A, Malloy P, & LaPadula M. Adult outcome of hyperactive boys: Educational achievement, occupational rank, and psychiatric status. Arch. Gen. Psychiatry 1993; 50(7): 565-576.
• Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods A. G, & Arnold L. E. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC medicine 2012; 10: 1-15.
• Rao K, Carpenter D. M, & Campbell C. I. Attention-deficit/hyperactivity disorder medication adherence in the transition to adulthood: associated adverse outcomes for females and other disparities. Journal of Adolescent Health 2021; 69(5): 806-814.
• Ahmed R, Aslani P. Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults. Expert Rev. Pharmacoeconomics Outcomes Res 2013; 13(6): 791-815.
• Lachaine J, Beauchemin C, Sasane R, & Hodgkins P. S. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. Postgraduate medicine 2012; 124(3): 139-148.
• Wehmeier P. M, Dittmann R. W, & Banaschewski T. Treatment compliance or medication adherence in children and adolescents on ADHD medication in clinical practice: results from the COMPLY observational study. ADHD Attention Deficit and Hyperactivity Disorders 2015; 7: 165-174.
• Barner J. C, Khoza S, & Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr. Med. Res. Opin. 2011; 27(sup2): 13-22.
• Bhang S. Y, Kwack Y. S, Joung Y. S, Lee S. I, Kim B, Sohn S. H, Hwang J. W. Factors that affect the adherence to ADHD medications during a treatment continuation period in children and adolescents: a nationwide retrospective cohort study using Korean Health Insurance data from 2007 to 2011. Psychiatry Investigation 2017; 14(2): 158.
• Zetterqvist J, Asherson P, Halldner L, Långström N, Larsson H. Stimulant and non‐stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006–2009. Acta Physiol. Scand 2013; 128(1): 70-77.
• Adler L.D, Nierenberg A. A. Review of medication adherence in children and adults with ADHD. Postgraduate medicine 2010; 122(1): 184-191.
• Morisky D.E, Green L.W, Levine D.M. (Concurrent and predictive validity of a self-reported measure of medication adherence. Medical care 1986; 1: 67-74.
• Yılmaz S. Psikiyatri Hastalarında İlaç Yan Etkileri ve İlaç Uyumu. Yüksek Lisans Tezi, İstanbul Üniversitesi, Sağlık Bilimleri Enstitüsü, 2004.
• Conners C.K, Sitarenios G, Parker J. D, Epstein J. N. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. Journal of abnormal child psychology 1998; 26: 257-268.
• Kaner S, Büyüköztürk Ş, İşeri E, Ak A, Özaydın L. Conners. Anababa Dereceleme Ölçeği Yenilenmiş Uzun Formu: Faktör Yapısı, Geçerlik Ve Güvenirlik Çalışması. Çocuk ve Gençlik Ruh Sağlığı Dergisi 2011; 18(1):45-58
• Safavi P, Saberzadeh M, Tehrani A. M. Factors associated with treatment adherence in children with attention deficit hyperactivity disorder. Indian J. Psychol. Med. 2019; 41(3): 252-257.
• Emilsson M, Gustafsson P.A, Öhnström G, Marteinsdottir I. Beliefs regarding medication and side effects influence treatment adherence in adolescents with attention deficit hyperactivity disorder. European child & adolescent psychiatry 2017; 26: 559-571.
• Thiruchelvam D, Charach A, Schachar R.J. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. Journal of the American Academy of Child & Adolescent Psychiatry 2001; 40(8): 922-928.
• Gau S.S.F, Chen S.J, Chou W.J, Cheng H, Tang C.S, Chang H.L, Huang Y. S. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Journal of Clinical Psychiatry 2008; 69(1):131.
• Atzori P, Usala T, Carucci S, Danjou F, Zuddas A. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J. Child Adolesc. Psychopharmacol. 2009; 19(6): 673-681.
• Zheng X, Shen L, Jiang L, Shen X, Xu Y, Yu G, & Wang Y. Parent and teacher training increases medication adherence for primary school children with attention-deficit/hyperactivity disorder. Front. Pediatr. 2020; 8: 486353.
• Nayak A.S, Nachane H.B, Keshari P, Parkar S.R, Saurabh K.H, & Arora M. Prescription patterns and medication adherence in preadolescent children with attention deficit hyperactivity disorder. Indian Journal of Psychiatry 2021; 63(3): 274.